Inspira Technologies Reports Disappointing FY Revenue and Increased Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy IINN?
Source: seekingalpha
- Disappointing Financial Performance: Inspira Technologies reported FY 2025 revenue of $0.3 million, missing expectations by $0.19 million, indicating significant pressure in market competition that may affect future financing capabilities.
- Increased R&D Expenses: For the twelve months ending December 31, 2025, R&D expenses rose to $7.496 million from $6.323 million in 2024, reflecting an 18.5% increase; however, this spending has not effectively translated into revenue, highlighting slow progress in technology development.
- Widening Net Loss: The net loss for FY 2025 was $13.22 million, a 19.6% increase from the $11.053 million loss in 2024, raising concerns among investors about the company's financial health and potentially impacting stock performance.
- Tightening Cash Flow: As of December 31, 2025, cash and cash equivalents totaled $3.159 million, down 45.4% from $5.779 million in 2024, indicating reduced liquidity that may constrain the company's operational and growth capabilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IINN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IINN
About IINN
Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspira Technologies Reports Disappointing FY Revenue and Increased Losses
- Disappointing Financial Performance: Inspira Technologies reported FY 2025 revenue of $0.3 million, missing expectations by $0.19 million, indicating significant pressure in market competition that may affect future financing capabilities.
- Increased R&D Expenses: For the twelve months ending December 31, 2025, R&D expenses rose to $7.496 million from $6.323 million in 2024, reflecting an 18.5% increase; however, this spending has not effectively translated into revenue, highlighting slow progress in technology development.
- Widening Net Loss: The net loss for FY 2025 was $13.22 million, a 19.6% increase from the $11.053 million loss in 2024, raising concerns among investors about the company's financial health and potentially impacting stock performance.
- Tightening Cash Flow: As of December 31, 2025, cash and cash equivalents totaled $3.159 million, down 45.4% from $5.779 million in 2024, indicating reduced liquidity that may constrain the company's operational and growth capabilities.
See More
Inspira Technologies Reports 2025 Financial Results and Strategic Updates
- Clinical Validation Progress: In April 2025, Inspira successfully treated its first patient using the ART100 system at Westchester Medical Center, marking a critical milestone in validating the system's real-world clinical performance, with subsequent deployments at multiple leading medical centers in the U.S. expanding its clinical application.
- Initial Commercial Success: In mid-2025, Inspira secured binding purchase orders totaling $49.5 million, representing its first large-scale commercial commitments, with revenue expected to be primarily recognized in 2026, demonstrating the company's initial success in the medical device market.
- Increased R&D Spending: Research and development expenses reached $7.496 million in 2025, up from $6.323 million in 2024, primarily due to higher share-based compensation and exchange rate fluctuations, reflecting the company's ongoing investment in technology development.
- Enhanced Liquidity: The company completed a registered direct offering at year-end, raising approximately $4.75 million, strengthening its liquidity to support commercial execution and strategic initiatives in 2026, ensuring compliance with Nasdaq's shareholder equity requirements for continued listing.
See More
Inspira Technologies Deploys ART100 System at Leading U.S. Hospital
- Market Expansion: Inspira Technologies has deployed its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center, further expanding its presence in the Tier-1 hospital market, which is expected to enhance the company's market share in the medical device sector.
- Clinical Evaluation Initiation: The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation aimed at defining clinical protocols and facilitating broader institutional adoption, paving the way for future commercialization.
- Strategic Execution: Mike Hershkovitz, Global VP Sales, stated that this deployment represents a continued execution of the company's U.S. commercial strategy, demonstrating that the ART100 meets the operational and clinical demands of top-tier healthcare providers, thereby strengthening the company's competitive position in the industry.
- Future Development Potential: Inspira Technologies is advancing the development of the next-generation INSPIRA ART500 system, designed to provide oxygenation support while patients remain awake, further solidifying its market position within the life-support and MedTech landscape.
See More
Inspira Technologies Showcases FDA-Cleared ART100 System
- Strategic Showcase: Inspira Technologies will present its FDA-cleared INSPIRA™ ART100 system at the AmSECT International Conference from March 25-29, 2026, in Austin, Texas, aiming to engage clinical decision-makers who influence hospital purchasing decisions and enhance market visibility.
- Leveraging FDA Approval: The ART100 system, which received FDA 510(k) clearance in May 2024, will be showcased to validate its readiness for clinical integration in cardiopulmonary bypass procedures, thereby accelerating market penetration.
- Active Distribution Channel: The collaboration with Glo-Med Networks Inc. for the presentation demonstrates Inspira's active commercial pipeline, marking a transition from development to sales execution and market visibility, enhancing its competitive position.
- Key Phase in Commercial Strategy: Global VP Sales Mike Hershkovitz noted that this event represents a critical phase in the company's U.S. commercial strategy, aimed at expanding clinical partnerships and distribution footprint to drive rapid market share growth.
See More
Inspira Technologies Secures Major Procurement Approval
- Stock Surge: Inspira Technologies OXY (IINN) shares surged over 28% in pre-market trading on Monday, reflecting strong market interest and heightened investor confidence in the company's new product.
- Procurement Approval: Israel's largest health services provider, Clalit Health Services, approved the procurement of Inspira's FDA-cleared ART100 platform, marking a significant milestone in the medical device sector for the company.
- Market Reach: The ART100 system will be rapidly deployed across Clalit’s healthcare network, which serves approximately 4.9 million members, indicating a swift expansion of the company's market share and enhanced brand presence.
- Clinical Validation: The approval of ART100 represents not only a successful regulatory clearance but also strong clinical validation for its application in cardiopulmonary bypass and ECMO procedures, signaling substantial future commercial growth potential.
See More
Inspira Technologies Secures Clalit Approval for ART100 System
- Commercial Activation: Inspira Technologies' INSPIRA™ ART100 system has received approval from Clalit Health Services, marking its transition to commercial availability within a network serving approximately 4.9 million members, which is expected to significantly enhance the company's competitiveness in the medical device market.
- Network Scale: Clalit operates 14 major hospitals and over 1,600 clinics, and this approval allows the ART100 to penetrate one of the most sophisticated healthcare supply chains globally, further solidifying Inspira's market position in high-end medical devices.
- Clinical Value Validation: Following a rigorous technical and clinical review, the ART100's safety and efficacy have been strongly validated, providing a powerful reference case for Inspira's promotion in other global health systems and enhancing its market credibility.
- Long-Term Revenue Foundation: CEO Dagi Ben-Noon stated that this approval lays the groundwork for potentially long-term, high-quality revenue, and is expected to accelerate the company's commercialization efforts in the U.S. and other global markets.
See More
Inspira Technologies Reports Disappointing FY Revenue and Increased Losses
- Disappointing Financial Performance: Inspira Technologies reported FY 2025 revenue of $0.3 million, missing expectations by $0.19 million, indicating significant pressure in market competition that may affect future financing capabilities.
- Increased R&D Expenses: For the twelve months ending December 31, 2025, R&D expenses rose to $7.496 million from $6.323 million in 2024, reflecting an 18.5% increase; however, this spending has not effectively translated into revenue, highlighting slow progress in technology development.
- Widening Net Loss: The net loss for FY 2025 was $13.22 million, a 19.6% increase from the $11.053 million loss in 2024, raising concerns among investors about the company's financial health and potentially impacting stock performance.
- Tightening Cash Flow: As of December 31, 2025, cash and cash equivalents totaled $3.159 million, down 45.4% from $5.779 million in 2024, indicating reduced liquidity that may constrain the company's operational and growth capabilities.
See More
Inspira Technologies Reports 2025 Financial Results and Strategic Updates
- Clinical Validation Progress: In April 2025, Inspira successfully treated its first patient using the ART100 system at Westchester Medical Center, marking a critical milestone in validating the system's real-world clinical performance, with subsequent deployments at multiple leading medical centers in the U.S. expanding its clinical application.
- Initial Commercial Success: In mid-2025, Inspira secured binding purchase orders totaling $49.5 million, representing its first large-scale commercial commitments, with revenue expected to be primarily recognized in 2026, demonstrating the company's initial success in the medical device market.
- Increased R&D Spending: Research and development expenses reached $7.496 million in 2025, up from $6.323 million in 2024, primarily due to higher share-based compensation and exchange rate fluctuations, reflecting the company's ongoing investment in technology development.
- Enhanced Liquidity: The company completed a registered direct offering at year-end, raising approximately $4.75 million, strengthening its liquidity to support commercial execution and strategic initiatives in 2026, ensuring compliance with Nasdaq's shareholder equity requirements for continued listing.
See More
Inspira Technologies Deploys ART100 System at Leading U.S. Hospital
- Market Expansion: Inspira Technologies has deployed its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center, further expanding its presence in the Tier-1 hospital market, which is expected to enhance the company's market share in the medical device sector.
- Clinical Evaluation Initiation: The ART100 system has been integrated into the center's clinical workflow to support a structured evaluation aimed at defining clinical protocols and facilitating broader institutional adoption, paving the way for future commercialization.
- Strategic Execution: Mike Hershkovitz, Global VP Sales, stated that this deployment represents a continued execution of the company's U.S. commercial strategy, demonstrating that the ART100 meets the operational and clinical demands of top-tier healthcare providers, thereby strengthening the company's competitive position in the industry.
- Future Development Potential: Inspira Technologies is advancing the development of the next-generation INSPIRA ART500 system, designed to provide oxygenation support while patients remain awake, further solidifying its market position within the life-support and MedTech landscape.
See More
Inspira Technologies Showcases FDA-Cleared ART100 System
- Strategic Showcase: Inspira Technologies will present its FDA-cleared INSPIRA™ ART100 system at the AmSECT International Conference from March 25-29, 2026, in Austin, Texas, aiming to engage clinical decision-makers who influence hospital purchasing decisions and enhance market visibility.
- Leveraging FDA Approval: The ART100 system, which received FDA 510(k) clearance in May 2024, will be showcased to validate its readiness for clinical integration in cardiopulmonary bypass procedures, thereby accelerating market penetration.
- Active Distribution Channel: The collaboration with Glo-Med Networks Inc. for the presentation demonstrates Inspira's active commercial pipeline, marking a transition from development to sales execution and market visibility, enhancing its competitive position.
- Key Phase in Commercial Strategy: Global VP Sales Mike Hershkovitz noted that this event represents a critical phase in the company's U.S. commercial strategy, aimed at expanding clinical partnerships and distribution footprint to drive rapid market share growth.
See More
Inspira Technologies Secures Major Procurement Approval
- Stock Surge: Inspira Technologies OXY (IINN) shares surged over 28% in pre-market trading on Monday, reflecting strong market interest and heightened investor confidence in the company's new product.
- Procurement Approval: Israel's largest health services provider, Clalit Health Services, approved the procurement of Inspira's FDA-cleared ART100 platform, marking a significant milestone in the medical device sector for the company.
- Market Reach: The ART100 system will be rapidly deployed across Clalit’s healthcare network, which serves approximately 4.9 million members, indicating a swift expansion of the company's market share and enhanced brand presence.
- Clinical Validation: The approval of ART100 represents not only a successful regulatory clearance but also strong clinical validation for its application in cardiopulmonary bypass and ECMO procedures, signaling substantial future commercial growth potential.
See More
Inspira Technologies Secures Clalit Approval for ART100 System
- Commercial Activation: Inspira Technologies' INSPIRA™ ART100 system has received approval from Clalit Health Services, marking its transition to commercial availability within a network serving approximately 4.9 million members, which is expected to significantly enhance the company's competitiveness in the medical device market.
- Network Scale: Clalit operates 14 major hospitals and over 1,600 clinics, and this approval allows the ART100 to penetrate one of the most sophisticated healthcare supply chains globally, further solidifying Inspira's market position in high-end medical devices.
- Clinical Value Validation: Following a rigorous technical and clinical review, the ART100's safety and efficacy have been strongly validated, providing a powerful reference case for Inspira's promotion in other global health systems and enhancing its market credibility.
- Long-Term Revenue Foundation: CEO Dagi Ben-Noon stated that this approval lays the groundwork for potentially long-term, high-quality revenue, and is expected to accelerate the company's commercialization efforts in the U.S. and other global markets.
See More
